Business Description
Xenetic Biosciences Inc
NAICS : 325411
SIC : 2834
ISIN : US9840156023
Total Employee Number:
2Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.88 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -30.95 | |||||
Beneish M-Score | -2.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.4 | |||||
3-Year EBITDA Growth Rate | 29.3 | |||||
3-Year EPS without NRI Growth Rate | 30 | |||||
3-Year FCF Growth Rate | 28.1 | |||||
3-Year Book Growth Rate | -28.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 55.34 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 39.97 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.93 | |||||
Quick Ratio | 7.93 | |||||
Cash Ratio | 7.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.7 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -75.05 | |||||
Net Margin % | -70.03 | |||||
EBITDA Margin % | -75.05 | |||||
FCF Margin % | -57.17 | |||||
OCF Margin % | -57.17 | |||||
ROE % | -40.07 | |||||
ROA % | -34.38 | |||||
ROIC % | -743.48 | |||||
3-Year ROIIC % | -504.94 | |||||
ROCE % | -42.94 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.6 | |||||
PB Ratio | 0.93 | |||||
Price-to-Tangible-Book | 0.93 | |||||
EV-to-EBIT | 0.38 | |||||
EV-to-EBITDA | 0.38 | |||||
EV-to-Revenue | -0.28 | |||||
EV-to-Forward-Revenue | 19.37 | |||||
EV-to-FCF | 0.5 | |||||
Price-to-GF-Value | 0.67 | |||||
| Price-to-Net-Current-Asset-Value | 0.97 | |||||
| Price-to-Net-Cash | 1.01 | |||||
Earnings Yield (Greenblatt) % | 263.16 | |||||
FCF Yield % | -28.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xenetic Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.739 | ||
| EPS (TTM) (€) | -1.032 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -35.58 | ||
| 3-Year Sortino Ratio | -3.45 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 3.1 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 3.1 - 3.1 | ||
| Shares Outstanding (Mil) | 2.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xenetic Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xenetic Biosciences Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-11 10:00 | In 144 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 23 days | ||
| First quarter earnings results for 2026 | 2026-05-12 | 3.10 (+0.00%) | ||
| Annual report for 2025 | 2026-03-12 | 3.10 (+0.00%) | ||
| General meeting for 2025 | 2025-12-11 10:00 | 3.10 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 3.10 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 3.10 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 3.10 (+0.00%) | ||
| Annual report for 2024 | 2025-03-18 | 3.10 (+0.00%) |
Show
Entries
Xenetic Biosciences Inc Frequently Asked Questions
What is Xenetic Biosciences Inc(STU:3XB0)'s stock price today?
The current price of STU:3XB0 is €3.10. The 52 week high of STU:3XB0 is €3.10 and 52 week low is €3.10.
When is next earnings date of Xenetic Biosciences Inc(STU:3XB0)?
The next earnings date of Xenetic Biosciences Inc(STU:3XB0) is 2026-08-13 Est..
Does Xenetic Biosciences Inc(STU:3XB0) pay dividends? If so, how much?
Xenetic Biosciences Inc(STU:3XB0) does not pay dividend.
Press Release
Articles on Xenetic Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers